Results 171 to 180 of about 133,761 (337)
ABSTRACT Cancer stem cells (CSCs) are widely recognized as the culprits of chemoresistance, tumor metastasis, and relapse. Moreover, most chemotherapeutic drugs not only fail to eliminate CSCs effectively, but also induce the acquisition of stemness characteristics in non‐stem cancer cells. Herein, we propose a cancer cells/CSCs double‐killing modality
Tongyao Zhao +10 more
wiley +1 more source
Chemoresistance of PRAME-expressing melanoma cell can be resolved with help of bortezomib
V. A. Misyurin +11 more
openalex +2 more sources
Role of Long Non-Coding RNAs in the Chemoresistance of Gastric Cancer: A Systematic Review
Zonglin Li +7 more
openalex +2 more sources
Figure S1 from Mitochondria Transfer from Mesenchymal Stem Cells Confers Chemoresistance to Glioblastoma Stem Cells through Metabolic Rewiring [PDF]
Jean Nakhle +19 more
openalex +1 more source
Osteosarcoma (OS) presents significant treatment challenges due to chemoresistance. This study explores the molecular mechanisms underlying chemoresistance in OS, focusing on the novel fusion gene RPS27-RPS24. Using single-cell multi-omics techniques, we
Zhiwei Tao +5 more
doaj +1 more source
The PIK3CA Mutation in Advanced Breast Cancer Chemoresistance and Recurrence [PDF]
Movchan Oleksii Volodimirovich +6 more
openalex +1 more source
Advanced extracellular vesicle immunotherapy
A diagrammatic depiction of the therapeutic applicability of extracellular vesicles (EVs) in immunotherapy. This review explores the dual roles of tumor‐derived and immune cell‐derived EVs in cancer immunotherapy, discusses recent progress in EV engineering that improve their clinical utility, and evaluates their potential to augment existing ...
Jingjing Zhang +6 more
wiley +1 more source
Retraction Note: RCC2 contributes to tumor invasion and chemoresistance to cisplatin in hepatocellular carcinoma [PDF]
Qingmin Chen +4 more
openalex +1 more source
What's New? Most patients with ovarian cancer (OC) relapse after first‐line chemotherapy, and prognosis with second‐line treatment depends largely on the platinum‐free interval. However, reliable biomarkers to predict response to second‐line therapy remain lacking.
Muhammad Habiburrahman +7 more
wiley +1 more source

